相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer
Karim S. El-Sahwi et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
The more things change the more they stay the same
David G. Mutch
GYNECOLOGIC ONCOLOGY (2012)
The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
K. El-Sahwi et al.
BRITISH JOURNAL OF CANCER (2010)
Specific targeting of anti-CD59 siRNA by Herceptin®-conjugated liposomes improves complement-mediated cytotoxicity of breast carcinoma cells
W. Li et al.
MOLECULAR IMMUNOLOGY (2009)
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial. carcinoma: A gynecologic oncology group study
T. A. Grushko et al.
GYNECOLOGIC ONCOLOGY (2008)
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
Alessandro D. Santin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2008)
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab
Paolo Macor et al.
CANCER RESEARCH (2007)
Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo
Achim Aigner
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2007)
Lipid-based nanoparticles for nucleic acid delivery
Weijun Li et al.
PHARMACEUTICAL RESEARCH (2007)
HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications
J. A. Villella et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
HER-2 is an independent prognostic factor in endometrial cancer: Association with outcome in a large cohort of surgically staged patients
C Morrison et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
被撤回的出版物: p53 regulates cellular resistance to complement lysis through enhanced expression of CD59(Retracted article. See vol. 73, pg. 6838, 2013)
RM Donev et al.
CANCER RESEARCH (2006)
Clinical significance of Her-2/neu overexpression in uterine serous carcinoma
TP Diaz-Montes et al.
GYNECOLOGIC ONCOLOGY (2006)
The management of serous papillary uterine cancer
Peter E. Schwartz
CURRENT OPINION IN ONCOLOGY (2006)
Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs
KA Gelderman et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2005)
Amplification of c-erbB2 oncogene - A maior prognostic indicator in uterine serous papillaty carcinoma
AD Santin et al.
CANCER (2005)
Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization
AD Santin et al.
GYNECOLOGIC ONCOLOGY (2005)
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): A major prognostic indicator in uterine serous papillary cancer
AD Santin et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2005)
Complement function in mAb-mediated cancer immunotherapy
KA Gelderman et al.
TRENDS IN IMMUNOLOGY (2004)
Downregulation of NK cell-mediated swine endothelial cell lysis by DAF (CD55)
T Kusama et al.
TRANSPLANTATION PROCEEDINGS (2003)
Expression of rat complement control protein Crry on tumor cells inhibits rat natural killer cell-mediated cytotoxicity
TA Caragine et al.
BLOOD (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
